Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Specker

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 20, 2020
[Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)]Carsten Oliver Schmidt, Klaus-Peter Günther, Jens Goronzy, et al.
Medicine|August 13, 2015
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter StudyLorenzo Cavagna, Laura Nuño, Carlo Alberto Scirè, et al.
Clinical Reviews in Allergy & Immunology|January 20, 2016
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative GroupLorenzo Cavagna, Laura Nuño, Carlo Alberto Scirè, et al.
The Journal of Rheumatology|November 17, 2018
Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International StudyMarco Sebastiani, Konstantinos Triantafyllias, Andreina Manfredi, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Arthritis Care & Research|August 29, 2023
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance RegistryJinoos Yazdany, Anna Ware, Zachary S Wallace, et al.
Annals of the Rheumatic Diseases|February 17, 2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology AllianceManuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, et al.
Annals of the Rheumatic Diseases|May 29, 2021
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registryJeffrey A Sparks, Zachary S Wallace, Andrea M Seet, et al.
Clinical and Experimental Rheumatology|August 4, 2017
Timing of onset affects arthritis presentation pattern in antisyntethase syndromeMiguel A González-Gay, Carlomaurizio Montecucco, Albert Selva-O'Callaghan, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 20, 2020
[Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)]Carsten Oliver Schmidt, Klaus-Peter Günther, Jens Goronzy, et al.
Medicine|August 13, 2015
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter StudyLorenzo Cavagna, Laura Nuño, Carlo Alberto Scirè, et al.
Clinical Reviews in Allergy & Immunology|January 20, 2016
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative GroupLorenzo Cavagna, Laura Nuño, Carlo Alberto Scirè, et al.
The Journal of Rheumatology|November 17, 2018
Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International StudyMarco Sebastiani, Konstantinos Triantafyllias, Andreina Manfredi, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Arthritis Care & Research|August 29, 2023
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance RegistryJinoos Yazdany, Anna Ware, Zachary S Wallace, et al.
Annals of the Rheumatic Diseases|February 17, 2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology AllianceManuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, et al.
Annals of the Rheumatic Diseases|May 29, 2021
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registryJeffrey A Sparks, Zachary S Wallace, Andrea M Seet, et al.
Clinical and Experimental Rheumatology|August 4, 2017
Timing of onset affects arthritis presentation pattern in antisyntethase syndromeMiguel A González-Gay, Carlomaurizio Montecucco, Albert Selva-O'Callaghan, et al.
Pageof 8